ClinicalTrials.gg
CompletedNCT05063318Updated Sep 2, 2025Results posted

Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

A Phase 1 interventional study of Lurbinectedin alone and Lurbinectedin+Itraconazole co-administration in Advanced Solid Tumors, sponsored by PharmaMar. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by PharmaMar · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2020, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors

Read the detailed description

Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors.

The study will include a pre-treatment (screening) phase (within 14 days before the first lurbinectedin or itraconazole administration) followed by a treatment phase consisting of two lurbinectedin cycles, one cycle in combination with itraconazole and one cycle as single agent (in different order depending on the study sequence), and one additional third cycle of lurbinectedin as a single agent for patients who meet the continuation criteria and obtain a clinical benefit after the first two cycles, and then follow-up of adverse events if any.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signed and dated written prior to any specific study procedure.
  2. Male or female with age ≥ 18 years.
  3. (ECOG) performance status (PS) of ≤ 1 (App. 1).
  4. > 3 months.
  5. confirmed diagnosis of advanced solid tumors [except for primary central nervous system (CNS) tumors], for which no standard therapy exists.
  6. Recovery to grade ≤ 1 from drug-related adverse events (AEs) of previous treatments, excluding alopecia and grade 1/2 asthenia or fatigue, according to the National Cancer Institute (NCICTCAE v.5).
  7. Laboratory values within fourteen days prior to Day 1 of Cycle 1
  8. (LVEF) by echocardiography (ECHO) or multiple-gated acquisition (MUGA) within normal range (according to institutional standards).
  9. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure up to six months after treatment discontinuation. Valid methods to determine the childbearing potential, adequate contraception and requirements for WOCBP partners are described in App. 2. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last medicinal product (IMP) dose.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diseases/conditions:

    1. History or presence of unstable angina, myocardial infarction, congestive heart failure, or valvular disease within last year.
    2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
    3. Known cirrhosis, alcohol induced steatosis, or chronic active hepatitis. For , this includes positive test for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR or HVB-DNA+). For , this includes positive test for both Hepatitis C antibody and quantitative Hepatitis C by PCR (or HVC-RNA+).
    4. History of obstructive cholestatic liver disease (suitable for stenting procedure) or biliary sepsis in the past 2 months.
    5. Known of active COVID-19 disease (this includes positive test for SARS-CoV- 2 in nasopharyngeal/oropharyngeal swabs or nasal swabs by PCR).
  2. Symptomatic, progressive or -requiring documented or involvement. Patients with asymptomatic documented stable brain metastases not requiring corticosteroids during the last four weeks are allowed.
  3. Use of (strong or moderate) inhibitors or inducers of activity within three weeks prior to Day 1 of Cycle 1.
  4. Use of CYP3A4 substrates such as HMG-CoA reductase inhibitors such as atorvastatin, lovastatin and simvastatin for which concomitant administration with strong CYP3A4 inhibitor is (App 3).
  5. Treatment with any product within the 30 days before Day 1 of Cycle 1.
  6. Women who are pregnant or breast feeding and fertile patients (men and women) who are not using an effective method of (see App 2).
  7. Psychiatric illness/social situations that would limit compliance with study requirements.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    Sequence TR

    Sequence 1 (TR) * Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m² * Cycle 2: Lurbinectedin alone 3.2 mg/m² * Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional) PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional). PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences.

    Drug: Lurbinectedin alone · Drug: Lurbinectedin+Itraconazole co-administration

  • Active comparator
    Sequence RT

    Sequence 2 (RT): * Cycle 1: Lurbinectedin alone 3.2 mg/m² * Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m² * Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)

    Drug: Lurbinectedin alone · Drug: Lurbinectedin+Itraconazole co-administration

Interventions

  • The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.

  • DrugLurbinectedin+Itraconazole co-administration

    Drug pages: PM 01183 · Itraconazole

    The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞)

    The primary parameter of interest for the statistical analysis will be plasma dose adjusted AUC(0-∞)

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

Secondary outcomes

  1. Pharmacokinetic Analysis: Dose-normalized AUC(0-t)

    The dose-normalized area under the concentration-time curve (AUC) will be calculated using the linear-log trapezoidal rule with extrapolation to infinity.

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

  2. Pharmacokinetic Analysis: Dose-normalized Cmax

    The maximum dose-normalized plasma concentration (Cmax) will be obtained directly from the experimental data.

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

  3. Pharmacokinetic Analysis: T1/2

    Terminal half-life (T1/2) will be obtained from the terminal rate constant calculated by linear regression using at least 3 observations.

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

  4. Pharmacokinetic Analysis: Total Body Clearance (CL)

    Total body clearance (CL), calculated by dividing the administered dose by the AUC with extrapolation to infinity.

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

  5. Pharmacokinetic Analysis: Volume of Distribution

    Volume of distribution (both at steady state and based on the terminal phase) (Vss and Vz, respectively): Vss is an estimate that equals mean residence time times total body clearance. Vz, calculated dividing the administered dose by the product of the AUC with extrapolation to infinity by the terminal rate constant

    Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)

07

Results

Posted Sep 2, 2025

Participant flow

14 patients were included and treated at 2 sites: 3 in Part A in Sequence 1 (S1 TR: ITZ+lurbinectedin in Cycle 1) and 11 in Part B, of them 5 in S1 and 6 in Sequence 2 (S2 RT: ITZ+lurbinectedin in Cycle 2). In Part A, all patients were assigned to S1 TR, while in Part B, patients were randomly assigned at a 1:1 ratio to S1 TR or S2 RT. Patients participated between 7Oct2020 and 3Mar2022 (last follow-up). The 1st dose of the 1st cycle on 15Oct2020. The last dose of the last cycle on 7Feb2022.

Participant flow — Overall Study
MilestonePart A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)
Started356
Completed000
Not completed356
Withdrew: Progressive disease203
Withdrew: Compassionate use133
Withdrew: Adverse event010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryPharmacokinetic Analysis: Dose-adjusted AUC(0-∞)

The primary parameter of interest for the statistical analysis will be plasma dose adjusted AUC(0-∞)

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · μg·h/L/mg
Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞)
μg·h/L/mgITZ+LRBLRB Alone
Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞)288.55 ± 73.9105.8 ± 77.37
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio: 272.73 · 90% CI 213.22 to 348.86ANOVA mixed-effects model included treatment, period and sequence as fixed effects, and patient (sequence) as a random effect
SecondaryPharmacokinetic Analysis: Dose-normalized AUC(0-t)

The dose-normalized area under the concentration-time curve (AUC) will be calculated using the linear-log trapezoidal rule with extrapolation to infinity.

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · μg·h/L/mg
Pharmacokinetic Analysis: Dose-normalized AUC(0-t)
μg·h/L/mgITZ+LRBLRB Alone
Pharmacokinetic Analysis: Dose-normalized AUC(0-t)244.77 ± 91.89103.4 ± 78.85
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio: 236.73 · 90% CI 177.35 to 316.00ANOVA mixed-effects model included treatment, period and sequence as fixed effects, and patient (sequence) as a random effect
SecondaryPharmacokinetic Analysis: Dose-normalized Cmax

The maximum dose-normalized plasma concentration (Cmax) will be obtained directly from the experimental data.

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · μg/L/mg
Pharmacokinetic Analysis: Dose-normalized Cmax
μg/L/mgITZ+LRBLRB Alone
Pharmacokinetic Analysis: Dose-normalized Cmax25.91 ± 53.1522.43 ± 53.75
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio.: 115.51 · 90% CI 100.07 to 133.33ANOVA mixed-effects model included treatment, period and sequence as fixed effects, and patient (sequence) as a random effect
SecondaryPharmacokinetic Analysis: T1/2

Terminal half-life (T1/2) will be obtained from the terminal rate constant calculated by linear regression using at least 3 observations.

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · hours
Pharmacokinetic Analysis: T1/2
hoursITZ+LRBLRB Alone
Pharmacokinetic Analysis: T1/2101.36 ± 6146.59 ± 17.12
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio.: 217.57 · 90% CI 151.81 to 311.82ANOVA mixed-effects model included treatment, period and sequence (TR or RT) as fixed effects, and patient (sequence) as a random effect.
SecondaryPharmacokinetic Analysis: Total Body Clearance (CL)

Total body clearance (CL), calculated by dividing the administered dose by the AUC with extrapolation to infinity.

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · L/h
Pharmacokinetic Analysis: Total Body Clearance (CL)
L/hITZ+LRBLRB Alone
Pharmacokinetic Analysis: Total Body Clearance (CL)3.47 ± 73.99.45 ± 77.37
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio: 36.67 · 90% CI 28.66 to 46.9ANOVA mixed-effects model included treatment, period and sequence as fixed effects, and patient (sequence) as a random effect
SecondaryPharmacokinetic Analysis: Volume of Distribution

Volume of distribution (both at steady state and based on the terminal phase) (Vss and Vz, respectively): Vss is an estimate that equals mean residence time times total body clearance. Vz, calculated dividing the administered dose by the product of the AUC with extrapolation to infinity by the terminal rate constant

Time frame:
Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Reported as:
Geometric mean · L
Pharmacokinetic Analysis: Volume of Distribution
LITZ+LRBLRB Alone
Pharmacokinetic Analysis: Volume of Distribution418.68 ± 111.45419.14 ± 58.58
Statistical analysis
  • ITZ+LRB vs LRB Alone · ANOVA · Least-squares geometric mean ratio: 99.89 · 90% CI 65.76 to 151.74ANOVA mixed-effects model included treatment, period and sequence as fixed effects, and patient (sequence) as a random effect

Adverse events

Collected over Three 21-days cycles. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ITZ+LRB Cycle1/13 (7.7%)4/13 (30.8%)12/13 (92.3%)
LRB Alone Cycle1/14 (7.1%)5/14 (35.7%)13/14 (92.9%)
Most frequent serious events
Most frequent serious events
EventITZ+LRB CycleLRB Alone Cycle
Alanine aminotransferase increasedInvestigations1/131/14
Pleural effusionRespiratory, thoracic and mediastinal disorders1/131/14
Small intestinal obstructionGastrointestinal disorders1/131/14
RhabdomyolysisMusculoskeletal and connective tissue disorders1/131/14
Intestinal obstructionGastrointestinal disorders1/131/14
Deep vein thrombosisVascular disorders0/131/14
Most frequent other events
Showing 10 of 24
Most frequent other events
EventITZ+LRB CycleLRB Alone Cycle
NeutropeniaBlood and lymphatic system disorders7/137/14
NauseaGastrointestinal disorders5/135/14
VomitingGastrointestinal disorders4/134/14
FatigueGeneral disorders4/134/14
ConstipationGastrointestinal disorders1/131/14
Bone painMusculoskeletal and connective tissue disorders1/131/14
DysgeusiaNervous system disorders1/131/14
SyncopeNervous system disorders1/131/14
CoughRespiratory, thoracic and mediastinal disorders1/131/14
DyspnoeaRespiratory, thoracic and mediastinal disorders1/131/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
<=18 years0000
Between 18 and 65 years1348
>=65 years2226
Age, Continuous
Age, Continuous(years)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
Median69 (49 to 72)64 (56 to 70)62 (56 to 72)63 (49 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
Female3249
Male0325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
White35614
Region of Enrollment
Region of Enrollment(participants)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
Spain35614
ECOG PS
ECOG PS(Participants)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
014510
12114
Weight
Weight(kg)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
Median58.9 (49.9 to 73.9)66.6 (50.0 to 102.9)69.5 (62.8 to 90.5)67.5 (49.9 to 102.9)
Height
Height(cm)Part A - S1 (TR)Part B - S1 (TR)Part B - S2 (RT)Total
Median165 (159 to 171)163 (152 to 172)166.5 (153 to 182)165 (152 to 182)

11 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital HM Sanchinarro
    Madrid, 28050, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Apr 2022, 18 months.

Results were first posted in Sep 2025, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Oct 1, 2021
StartActual
Oct 7, 2020
Primary completionActual
Apr 21, 2022
CompletionActual
Apr 21, 2022
Results first posted
Sep 2, 2025
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05063318
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Oct 7, 2020
Primary completion
Apr 21, 2022
Completion
Apr 21, 2022
Results posted
Sep 2, 2025
Last update
Sep 2, 2025

Study contacts

Sara Martínez Gonzalez, MD
study director · PharmaMar
Rubin Lubomirov, MD, PhD
study director · PharmaMar

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PM 01183 · Itraconazole

Start the discussion